# Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

> **NCT05263492** · PHASE2 · TERMINATED · sponsor: **Virginia Commonwealth University** · enrollment: 4 (actual)

## Conditions studied

- Endometrial Cancer
- Mismatch Repair-Proficient
- Recurrent Endometrial Cancer

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05263492
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-01
- **Primary completion:** 2024-09-13
- **Final completion:** 2024-10-19
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Closed early due to low enrollment rates
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263492, "Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05263492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*